New entrants to multiple sclerosis market will drive 10% pa growth through 2018
The market for disease-modifying multiple sclerosis (MS) therapies will expand at an annual rate of 10% through 2018, peaking at nearly $21 billion in that year in the top seven nations, according to health care advisory firm Decision Resources.
Market growth will be driven by the launch of at least six premium-priced disease-modifying therapies and forecast price increases in the US market. Among new entrants, Biogen Idec's (Nasdaq: BIIB) Tecfidera (dimethyl fumarate) is expected to have the greatest clinical and commercial success -owing to its compelling clinical profile - and will capture more than $4 billion in 2018 sales in the USA, France, Germany, Italy, Spain, the UK and Japan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze